Results 1 to 10 of about 11,328,563 (174)

Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. [PDF]

Front Neurosci
Alzheimer’s disease (AD) affects over 6 million people over the age of 65. The advent of new anti-amyloid monoclonal antibodies as treatment for early Alzheimer’s disease these immunotherapeutics may slow disease progression but also pose significant ...
Doran SJ, Sawyer RP.
europepmc   +8 more sources

Amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease: from pathophysiology to individualized risk assessment. [PDF]

Alzheimers Res Ther
Monoclonal antibodies targeting amyloid-β are the first approved disease-modifying treatment for Alzheimer’s disease. While amyloid-targeting therapies mitigate the progression of cognitive decline in early-stage Alzheimer’s disease, they are associated ...
Merkel J, Perneczky R, Jessen F, Frölich L, Jansen O, Peters S, Berg D, Schulz JB, Bartsch T.   +8 more
europepmc   +7 more sources

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2020
Introduction Amyloid‐related imaging abnormalities (ARIA) are a common, dose‐dependent effect of amyloid‐targeting antibodies, strongly associated with the apolipoprotein E (APOE) ε4 allele.
Lawren VandeVrede, Daniel M Gibbs, Mary Koestler, Renaud La Joie, Peter A. Ljubenkov, Karine Provost, David Soleimani‐Meigooni, Amelia Strom, Elena Tsoy, Gil D. Rabinovici, Adam L. Boxer   +10 more
doaj   +3 more sources

Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer's disease and a literature review. [PDF]

BMC Neurol
Objective To investigate the imaging characteristics and management strategies of amyloid-related imaging abnormalities (ARIA) in Alzheimer’s disease (AD) patients treated with lecanemab.
Wang Y, Yu Q, Chen B, Zhou J, Li Z, Liao W, Liu J, Yang A.   +7 more
europepmc   +4 more sources

Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer’s disease and cerebral amyloid angiopathy. [PDF]

Frontiers in Neurology, 2015
Amyloid Related Imaging Abnormalities (ARIA) represent the major severe side effect of amyloid-beta (Aβ) immunotherapy for Alzheimer’s disease (AD).
Jacopo C. DiFrancesco, Jacopo C. DiFrancesco, Martina eLongoni, Martina eLongoni, Fabrizio ePiazza, Fabrizio ePiazza, Fabrizio ePiazza   +6 more
doaj   +5 more sources

Spontaneous and Drug-Induced Amyloid-Related Imaging Abnormalities: Overlaps, Divergences, and Clinical Implications Across a Continuum Between Alzheimer’s Disease and Cerebral Amyloid Angiopathy

Biomolecules
Background: Amyloid-related imaging abnormalities (ARIA) have gained significance in the context of anti-amyloid therapies (AATs), exhibiting clinical and radiological manifestations that overlap with Cerebral Amyloid Angiopathy-related inflammation (CAA-
Marialuisa Zedde, Mattia Losa, Elena Grisafi, Davide D. Lucia, Ilaria Gandoglia, Massimo Del Sette, Matteo Pardini, Luca Roccatagliata, Rosario Pascarella, Fabrizio Piazza   +9 more
doaj   +4 more sources

Amyloid-related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid-modifying therapy. [PDF]

Ann Clin Transl Neurol
Amyloid‐related imaging abnormalities, were originally described by dementia care experts. The wider use of aducanumab and now lecanemab warrant broader understanding by the health care provider continuum.
Vukmir RB.
europepmc   +4 more sources

Lecanemab in practice: AI-derived MRI predictors of benefit and Amyloid Related Imaging Abnormalities (ARIA). [PDF]

Alzheimers Res Ther
Introduction Lecanemab, a monoclonal antibody targeting amyloid beta, has demonstrated meaningful clinical benefits in early Alzheimer’s disease (AD), yet real-world data is needed to optimize patient selection and enhance safety monitoring, particularly
Bregman N, de Barros NP, Nathan T, Levy MH, Sima D, Van Eyndhoven S, Bar-David A, Aizenstein O, Niry D, Atlan L, Awad AA, Ash E, Omer N, Shiner T.   +13 more
europepmc   +3 more sources

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

Frontiers in Neurology, 2022
Second-generation anti-amyloid monoclonal antibodies are emerging as a viable therapeutic option for individuals with prodromal and mild dementia due to Alzheimer's disease (AD).
Charles G. Withington, R. Scott Turner
doaj   +3 more sources

The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6

The Journal of Prevention of Alzheimer's Disease
The TRAILBLAZER-ALZ 6 study (NCT05738486) evaluated the effect of different donanemab dosing regimens on amyloid-related imaging abnormalities with edema/sulcal effusions (ARIA-E).
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Sergey Shcherbinin, Wen Xu, Scott W. Andersen, Paula M. Hauck, Dawn A. Brooks, Emily C. Collins, Stephen Salloway, Mark A. Mintun, John R. Sims   +13 more
doaj   +3 more sources